利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

79 条记录 (耗时 0.05 秒)

    Protease Inhibitors
    53.
    发明申请
    Protease Inhibitors 审中-公开
    蛋白酶抑制剂

    公开(公告)号：US20120108501A1

    公开(公告)日：2012-05-03

    申请号：US13375689

    申请日：2010-06-11

    申请人： Jennifer Riggs-Sauthier

    发明人： Jennifer Riggs-Sauthier

    IPC分类号： A61K31/4418 ,  A61P31/18 ,  A61K38/05 ,  A61K31/706 ,  C07D213/56 ,  C07H15/26

    CPC分类号： A61K47/60

    摘要： The invention relates to (among other things) protease inhibitors containing both a water-soluble, non-peptidic oligomer and a lipophilic moiety-containing residue. A compound of the invention, when administered by any of a number of administration routes, exhibits advantages over protease inhibitor compounds lacking the water-soluble, non-peptidic oligomer and a lipophilic moiety-containing residue.

    摘要翻译： 本发明涉及含有水溶性，非肽低聚物和含亲脂性部分残基的蛋白酶抑制剂（尤其是）。 当通过任何多种施用途径给药时，本发明的化合物显示出优于缺乏水溶性，非肽性寡聚物的蛋白酶抑制剂化合物和含亲脂性部分残基的优点。

    Immunoregulatory compounds and derivatives and methods of treating diseases therewith
    57.
    发明授权
    Immunoregulatory compounds and derivatives and methods of treating diseases therewith 有权
    免疫调节化合物及其治疗疾病的衍生物和方法

    公开(公告)号：US07425578B2

    公开(公告)日：2008-09-16

    申请号：US11470655

    申请日：2006-09-07

    申请人： Nnochiri N. Ekwuribe ,  Jennifer Riggs-Sauthier

    发明人： Nnochiri N. Ekwuribe ,  Jennifer Riggs-Sauthier

    IPC分类号： A61K31/16 ,  C07C245/06

    CPC分类号： A61K31/195 ,  A61K31/196 ,  A61K31/215 ,  A61K31/24 ,  C07C229/42 ,  C07C245/08 ,  Y02A50/475 ,  Y02A50/481 ,  A61K2300/00

    摘要： Compounds are disclosed having the structure of Formula I: where R1, R3, and R4 are independently hydrogen or C1 to C4 alkyl, and R2 is: where R5 is selected from the group consisting of hydrogen and C1 to C4 alkyl, or where R6, R7 and R8 are independently hydrogen or C1 to C4 alkyl; or the esters or pharmacologically acceptable salts thereof. Such compounds may be utilized for the prophylaxis or treatment of various diseases, particularly inflammatory conditions of the GI tract. Methods of treating inflammatory conditions of the GI tract such as inflammatory bowel disease using compounds having the following formula are also disclosed: where R9, R10 and R11 are independently selected from the group consisting of hydrogen and C1 to C4 alkyl, and R12 is selected from the group consisting of hydrogen and —C(O)R13, where R13 is a C1 to C6 alkyl or an aryl group.

    摘要翻译： 公开了具有式I结构的化合物：其中R 1，R 3和R 4独立地是氢或C 1 C 1至C 4烷基，R 2是：其中R 5选自氢和C C 1至C 4烷基，或其中R 6，R 7和R 8是 独立地是氢或C 1至C 4烷基; 或其酯或药理学上可接受的盐。 这些化合物可用于预防或治疗各种疾病，特别是GI道的炎性病症。 还公开了使用具有下式的化合物治疗胃肠道炎症性疾病如炎症性肠病的方法：其中R 9，R 10和R 11 独立地选自氢和C 1至C 4烷基，R 12选自基团 由氢和-C（O）R 13组成，其中R 13是C 1至C 6 - 烷基或芳基。

    Immunoregulatory compounds and derivatives and methods of treating diseases therewith
    58.
    发明申请
    Immunoregulatory compounds and derivatives and methods of treating diseases therewith 有权
    免疫调节化合物及其治疗疾病的衍生物和方法

    公开(公告)号：US20050054728A1

    公开(公告)日：2005-03-10

    申请号：US10967736

    申请日：2004-10-18

    申请人： Nnochiri Ekwuribe ,  Jennifer Riggs-Sauthier

    发明人： Nnochiri Ekwuribe ,  Jennifer Riggs-Sauthier

    IPC分类号： A61P1/04 ,  A61K31/194 ,  A61K31/195 ,  A61K31/196 ,  A61K31/215 ,  A61K31/606 ,  A61P1/00 ,  A61P29/00 ,  A61P43/00 ,  C07C245/08

    CPC分类号： A61K31/195 ,  A61K31/196 ,  A61K31/215 ,  A61K31/24 ,  C07C229/42 ,  C07C245/08 ,  Y02A50/475 ,  Y02A50/481 ,  A61K2300/00

    摘要： Compounds are disclosed having the structure of Formula I: where R1, R3, and R4 are independently hydrogen or C1 to C4 alkyl, and R2 is: where R5 is selected from the group consisting of hydrogen and C1 to C4 alkyl, or where R6, R7 and R8 are independently hydrogen or C1 to C4 alkyl; or the esters or pharmacologically acceptable salts thereof. Such compounds may be utilized for the prophylaxis or treatment of various diseases, particularly inflammatory conditions of the GI tract. Methods of treating inflammatory conditions of the GI tract such as inflammatory bowel disease using compounds having the following formula are also disclosed: where R9, R10 and R11 are independently selected from the group consisting of hydrogen and C1 to C4 alkyl, and R12 is selected from the group consisting of hydrogen and —C(O)R13, where R13 is a C1 to C6 alkyl or an aryl group.

    摘要翻译： 公开了具有式I结构的化合物：其中R 1，R 3和R 4独立地是氢或C 1至C 4烷基，R 2是：其中R 5选自 由氢和C 1至C 4烷基组成的组，或其中R 6，R 7和R 8独立地为氢或C 1至C 4烷基; 或其酯或药理学上可接受的盐。 这些化合物可用于预防或治疗各种疾病，特别是GI道的炎性病症。 还公开了使用具有下式的化合物治疗胃肠道炎症状况如炎性肠病的方法：其中R 9，R 10和R 11独立地选自氢和C 1 至C 4烷基，R 12选自氢和-C（O）R 13，其中R 13为C 1至C 6烷基或芳基。